Inimmune's INI-4001: A New Immunotherapy for Breast Cancer

🩷 Breast Cancer Awareness Month Spotlight: Tumor Markers Every breast cancer diagnosis begins with a commitment to precision and care. This October, API recognizes the vital role laboratorians play in supporting patient care through reliable oncology testing, bringing clarity, confidence, and hope to patients. Through API’s Tumor Markers Program (#183), laboratories can assess key biomarkers essential to breast cancer management, including: ➡️ CA 15-3 – can be indicative of breast cancer and is used to monitor treatment response and disease recurrence ➡️ CA 27.29 – used to monitor treatment effectiveness and detect early recurrence of breast cancer API provides fifteen samples over three shipments per year, helping laboratories maintain regulatory compliance and confidence in their tumor marker testing — because quality results can make all the difference in patient care. 🔗 Explore Program #183 in the API Catalog: https://api-pt.com/catalog #BreastCancerAwarenessMonth #BreastCancerAwareness #CancerDiagnostics #API #ProficiencyTesting #LaboratoryExcellence #QualityInTheLab

October is Breast Cancer Awareness Month. Reliable laboratory testing helps guide care decisions, track treatment responses, and provide reassurance for patients experiencing breast cancer. We’re proud to provide support to practitioners and patients with lab testing through our network, including: CA 15-3 - a protein and tumor marker associated with breast cancer. It's used in blood tests to monitor advanced-stage cancer treatment response and to check for recurrence: https://lnkd.in/grMrdz8X Carcinoembryonic antigen (CEA) - a protein that can indicate colon cancer. It can be used to determine if breast cancer has spread to other parts of the body. https://lnkd.in/g-sqHNcJ   #BreastCancerAwareness #LabTesting #PatientCare #Diagnostics  

VK Gadi, MD PhD and Anne ODea as they discuss advances in HER2-positive breast cancer treatment using antibody-drug conjugates (ADCs) such T-DXd and T-DM1 and hormone-positive and triple-negative breast cancer with sacituzumab govitecan. These trials demonstrate sacituzumab govitecan is better than chemotherapy for quality of life, making it a good option for all breast cancer subtypes. To improve metastatic breast cancer outcomes, ADC development must continue. 🎧 Don’t forget to like, share, and subscribe for more CHM Conversations #BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch

October is Breast Cancer Awareness Month A reminder that early detection saves lives, and timely, evidence-based care pathways can save even more. In 2025, an estimated 316,950 women and 2,800 men will be diagnosed with invasive breast cancer, and an additional 59,080 new cases of non-invasive (in situ) breast cancer will be diagnosed. Chances are, you know at least one person who has been personally affected by breast cancer.  At WNS-HealthHelp, our Oncology program supports health plans and providers with clinically guided pathways designed to: -Ensure the right tests at the right time -Reduce unnecessary delays in care -Improve outcomes while managing total cost of care Because when it comes to cancer, every decision and every day matters. Learn how we help payers and providers work together to achieve better oncology outcomes: https://lnkd.in/grZ3JiXU

🎀 Today marks Metastatic Breast Cancer Awareness Day—a crucial reminder of the ongoing need for scientific progress and regulatory excellence in treatment. Access the latest, regulatory-grade intelligence and breakthrough clinical insights on metastatic breast cancer via the https://lnkd.in/eeeDXqRK app. 🔔 10 Ongoing Clinical Trials On Immunotherapy In Breast Cancer https://lnkd.in/ebDEwd5C 🔔 Targeting Triple-negative Breast Cancer Using Cord-blood CD34⁺ HSPC-derived Mesothelin-specific CAR-NKT Cells With Potent Antitumor Activity https://lnkd.in/eG-U4mas Enhance decision-making with up-to-date, evidence-based information designed for healthcare professionals and industry experts. How are you advancing metastatic breast cancer care in your field? #MetastaticBreastCancer #OncologyInsights #RegulatoryIntelligence #ClinicalResearch #PharmaInnovation #BreastCancer

Breast cancer treatment is entering an exciting new era of innovation and personalization.  In a recent interview, Dr. Sarah Premji highlights how community-based clinical trials are critical for ensuring patients everywhere have access to cutting-edge therapies. Advances such as targeted treatments for ER-positive disease, novel HER2-directed agents, and immunotherapies for triple-negative breast cancer are transforming patient outcomes. The future of breast oncology lies in smarter sequencing, biomarker-driven strategies, and tailoring care to each patient. Read the full discussion from Targeted Oncology here: https://lnkd.in/ewfGcW5F

This week, Breast Cancer Canada stood alongside Brenda Cunnington at the market open to recognize Global Lobular Breast Cancer Awareness Day. Together we put a spotlight on the urgent need for innovation. Lobular breast cancer accounts for up to 15% of all breast cancer cases, yet it is often missed on standard imaging and responds differently to treatment than more common forms. Despite this, research and clinical pathways for lobular disease remain significantly underrepresented. Brenda is using her voice to change that, and so are we. At Breast Cancer Canada, we are investing in research and data innovation to improve early detection, precision treatment options, and patient outcomes for lobular breast cancer and beyond. Read Brenda’s story and support research: https://lnkd.in/edMfj8iF Progress happens when patients lead and research rises to meet their needs.

🎯 Risk-Adapted Adjuvant Therapy in Postmenopausal Women with Early Breast Cancer: Real-World Evidence from Denmark Led by Maj-Britt Jensen and Prof. Bent Ejlertsen, this large-scale, nationwide prospective cohort study by the Danish Breast Cancer Group (DBCG) analyzed outcomes in 8,921 postmenopausal women with ER-positive, HER2-negative early breast cancer. The study validated the Prognostic Standard Mortality Rate Index (PSI) as a reliable tool for tailoring adjuvant therapy. Notably, women categorized as PSI 1—treated with endocrine therapy alone—showed no excess mortality when chemotherapy was omitted. Conversely, patients in PSI 3–4 had significantly higher mortality despite full treatment, suggesting a need for intensified or novel therapeutic strategies. These findings support risk-adapted decision-making in early breast cancer care, optimizing treatment intensity while avoiding unnecessary toxicity. https://lnkd.in/ewNDHnNp #BreastCancer #OncologyFrontier #MediaMedic #DBCG #PrecisionOncology #EndocrineTherapy #AdjuvantTherapy #RiskStratification #ClinicalOutcomes

💊 Breast cancer treatment is evolving From targeted therapies to combination approaches, significant advances are shaping patient care and outcomes. Innovations like extended hormone therapy, immunotherapy, and new strategies for triple-negative and HER2-positive breast cancers are expanding the treatment landscape. These developments are providing patients and clinicians with more personalised options and hope for improved long-term outcomes. Staying informed on the latest evidence and emerging strategies is essential for healthcare professionals managing breast cancer care. 📌 Browse video highlights, short articles, and peer-reviewed journal content from major conferences to stay up to date: https://lnkd.in/exjVqgH7 Association of Cancer Care Centers #BreastCancerAwarenessMonth #EarlyDetection #Oncology #OncologyCare #BreastCancer

💊 Breast cancer treatment is evolving From targeted therapies to combination approaches, significant advances are shaping patient care and outcomes. Innovations like extended hormone therapy, immunotherapy, and new strategies for triple-negative and HER2-positive breast cancers are expanding the treatment landscape. These developments are providing patients and clinicians with more personalised options and hope for improved long-term outcomes. Staying informed on the latest evidence and emerging strategies is essential for healthcare professionals managing breast cancer care. 📌 Browse video highlights, short articles, and peer-reviewed journal content from major conferences to stay up to date: https://lnkd.in/exjVqgH7 Association of Cancer Care Centers #BreastCancerAwarenessMonth #EarlyDetection #Oncology #OncologyCare #BreastCancer